{"product_id":"natural-compounds-for-non-small-cell-lung-cancer-targeting-the-egfr-signaling-pathway","title":"Natural Compounds for Non-Small Cell Lung Cancer: Targeting the EGFR Signaling Pathway","description":"\u003cp\u003eThis review article summarizes current evidence on more than 33 natural compounds. These compounds include alkaloids, terpenoids, flavonoids, and polyphenols. They may help overcome resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). The authors describe how these plant-derived compounds work through multiple mechanisms at once: directly blocking EGFR activation, interfering with downstream signaling pathways, and triggering programmed cell death. The review also examines how new delivery technologies, such as nano-delivery systems, could overcome the poor absorption and rapid elimination that have limited these compounds in clinical use. The authors conclude that natural compounds should be viewed not as replacements for existing TKIs, but as essential partners in combination therapy strategies for patients with EGFR-mutant NSCLC.\u003c\/p\u003e\n\n\u003ch1\u003eNatural Compounds for Non-Small Cell Lung Cancer: Targeting the EGFR Signaling Pathway\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#egfr-pathway\"\u003eThe EGFR Signaling Pathway and Its Role in Treatment Resistance\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#egfr-structure\"\u003eKey Features of EGFR Structure and Cancer-Causing Mutations\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#signaling-cascades\"\u003eCore Signaling Cascades and How They Become Disrupted in Resistance\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#signal-attenuation\"\u003eHow the Body Normally Shuts Down EGFR Signals—and How This Fails in Cancer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#bypass-pathways\"\u003eCrosstalk with Bypass Pathways: The Center of Resistance\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#therapeutic-challenges\"\u003eTherapeutic Challenges and Strategic Opportunities\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#natural-compounds\"\u003eNatural Compounds Targeting the EGFR Pathway in NSCLC Therapy\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#alkaloids\"\u003eAlkaloids\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#terpenoids\"\u003eTerpenoids\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#flavonoids\"\u003eFlavonoids\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#polyphenols\"\u003ePolyphenols\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#other-compounds\"\u003eOther Natural Compounds\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Current Evidence\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eNatural compounds are not yet ready for routine clinical use; most evidence comes from laboratory and animal studies, and clinical trials in patients are still needed.\u003c\/li\u003e\n\u003cli\u003eThese compounds appear most promising alongside existing EGFR-TKIs, not as replacements, and may help restore sensitivity in resistant tumors.\u003c\/li\u003e\n\u003cli\u003eResistance to EGFR-TKIs involves many pathways, so compounds affecting multiple targets at once may be more effective than single-target drugs.\u003c\/li\u003e\n\u003cli\u003eMany natural compounds have poor bioavailability and are rapidly eliminated; nano-delivery systems may help overcome these limitations.\u003c\/li\u003e\n\u003cli\u003eComprehensive safety data at therapeutic doses are lacking for many compounds, including potential liver toxicity, gastrointestinal effects, and drug interactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eLung cancer remains the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. This means that about 85 in every 100 people diagnosed with lung cancer have the NSCLC type.\u003c\/p\u003e\n\n\u003cp\u003eThe discovery of activating mutations (changes) in the epidermal growth factor receptor (\u003cstrong\u003eEGFR\u003c\/strong\u003e) gene has transformed treatment for many patients. These mutations include exon 19 deletions and the L858R point mutation. EGFR tyrosine kinase inhibitors (\u003cstrong\u003eTKIs\u003c\/strong\u003e)—drugs including gefitinib, erlotinib, and osimertinib—have become the standard first-line therapy for patients with EGFR-mutant NSCLC. These drugs have shown remarkable clinical effectiveness.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the long-term benefit of EGFR-TKIs is always limited by the development of acquired resistance. This means that eventually, the cancer stops responding to the drug. This resistance now represents the most important clinical challenge in treating EGFR-mutant NSCLC.\u003c\/p\u003e\n\n\u003cp\u003eResistance mechanisms are complex and varied. They include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOn-target secondary EGFR mutations\u003c\/strong\u003e (new changes in the EGFR gene itself, such as T790M and C797S)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eActivation of bypass signaling pathways\u003c\/strong\u003e (other molecular pathways that circumvent the drug's effects, such as MET and AXL)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhenotypic transformations\u003c\/strong\u003e (changes in the character of cancer cells, such as epithelial-mesenchymal transition, or EMT)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis complexity highlights the limitations of treating one target at a time. There is an urgent need for innovative strategies that can address multiple parts of the resistance network simultaneously.\u003c\/p\u003e\n\n\u003cp\u003ePlant-derived natural compounds have emerged as a promising source of new therapeutic agents. Their diverse chemical structures, ability to affect multiple targets at once, and generally favorable safety profiles make them ideal candidates for combination therapies aimed at overcoming TKI resistance. Rather than simply replacing existing TKIs, these compounds may work by modulating the core EGFR pathway along with its connected networks. This could make resistant tumors sensitive to treatment again.\u003c\/p\u003e\n\n\u003ch2 id=\"egfr-pathway\"\u003eThe EGFR Signaling Pathway and Its Role in Treatment Resistance\u003c\/h2\u003e\n\n\u003cp\u003eThe EGFR pathway is a central regulator of cell growth and survival. When this pathway becomes abnormal, it acts as a principal cancer-causing driver in NSCLC. Treating mutant EGFR with TKIs initially produces high response rates. However, the inevitable emergence of acquired resistance remains a major clinical challenge.\u003c\/p\u003e\n\n\u003ch2 id=\"egfr-structure\"\u003eKey Features of EGFR Structure and Cancer-Causing Mutations\u003c\/h2\u003e\n\n\u003cp\u003eEGFR is a transmembrane receptor. This means it spans the cell membrane, with parts outside and inside the cell. It has three main sections:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAn extracellular ligand-binding domain (the part outside the cell that receives growth signals)\u003c\/li\u003e\n\u003cli\u003eA transmembrane anchor (the part that crosses the cell membrane)\u003c\/li\u003e\n\u003cli\u003eAn intracellular tyrosine kinase domain (the part inside the cell that sends growth signals)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCancer development in NSCLC is frequently driven by activating mutations within the kinase domain. The most common mutations are exon 19 deletions and the L858R point mutation. These mutations cause the receptor to signal constantly, even without a growth signal. They also make the cancer sensitive to first- and second-generation TKIs.\u003c\/p\u003e\n\n\u003cp\u003eThe acquisition of secondary mutations, such as T790M, restores the receptor's ability to bind ATP (the cell's energy molecule). This is a classic mechanism of resistance. The T790M mutation was later targeted by third-generation TKIs like osimertinib.\u003c\/p\u003e\n\n\u003ch2 id=\"signaling-cascades\"\u003eCore Signaling Cascades and How They Become Disrupted in Resistance\u003c\/h2\u003e\n\n\u003cp\u003eWhen a ligand (growth signal) binds to EGFR, the receptor pairs up with another EGFR molecule (dimerization) and activates itself through a process called autophosphorylation. This recruits adaptor proteins that activate downstream pathways critical for tumor survival. The two main pathways are:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eRAS\/RAF\/MEK\/ERK (MAPK) pathway\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePI3K\/Akt\/mTOR pathway\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn the context of resistance, these cascades can be reactivated even when EGFR is being blocked by a drug. For example, mutated EGFR variants often have impaired endocytosis (the process by which cells bring the receptor inside to be broken down). This leads to prolonged receptor retention at the cell membrane and sustained downstream signal output.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, persistent activation of pathways like JAK\/STAT can promote the expression of anti-apoptotic genes (genes that prevent cell death). This further contributes to treatment evasion.\u003c\/p\u003e\n\n\u003ch2 id=\"signal-attenuation\"\u003eHow the Body Normally Shuts Down EGFR Signals—and How This Fails in Cancer\u003c\/h2\u003e\n\n\u003cp\u003eUnder normal conditions, EGFR signaling is precisely controlled through a multi-layered attenuation (shut-down) system to prevent sustained proliferative signaling. The primary mechanism involves receptor downregulation via clathrin-mediated endocytosis. In this process, activated EGFR is internalized and sorted for either recycling back to the membrane or degradation in lysosomes (cellular recycling centers). This degradation follows ubiquitination by E3 ligases like Cbl.\u003c\/p\u003e\n\n\u003cp\u003eThis degradation pathway, mediated by the ESCRT complex, can shorten EGFR's half-life to under 1 hour. This provides a rapid termination mechanism for growth signals. At the same time, protein tyrosine phosphatases (PTPs) function as critical negative regulators. They directly remove phosphate groups from activated EGFR and its downstream effectors, thereby resetting the signaling cascade.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, intrinsic negative feedback loops—such as ERK-mediated inhibition of upstream SOS and EGFR, or mTORC1\/S6K1-induced suppression of IRS1—create self-limiting circuits that maintain signaling balance.\u003c\/p\u003e\n\n\u003cp\u003eIn NSCLC, particularly in the context of TKI resistance, these regulatory mechanisms are frequently subverted. Mutant EGFR variants often exhibit impaired endocytic trafficking and defective ubiquitination. This leads to prolonged membrane retention and constitutive (constant) signaling. The tumor microenvironment (TME)—the environment surrounding the tumor—may further suppress PTP activity or expression, disrupting the balance between phosphorylation and dephosphorylation.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, chronic TKI exposure can disrupt feedback mechanisms. This enables adaptive survival signaling through alternative nodes. This collective failure of the body's natural attenuation system not only contributes to cancer progression but also creates conditions that allow resistance to develop. Understanding these compromised regulatory checkpoints is essential for designing strategies to restore pathway control.\u003c\/p\u003e\n\n\u003ch2 id=\"bypass-pathways\"\u003eCrosstalk with Bypass Pathways: The Center of Resistance\u003c\/h2\u003e\n\n\u003cp\u003eA primary cause of TKI failure is the activation of alternative signaling networks that bypass EGFR dependence. The MET pathway, through gene amplification or overexpression, reactivates the shared PI3K\/Akt and MAPK cascades. This sustains survival signals independently of EGFR inhibition.\u003c\/p\u003e\n\n\u003cp\u003eAt the same time, dynamic crosstalk with the tumor microenvironment establishes a resilient pro-tumor loop. EGFR signaling upregulates immune checkpoint molecules such as PD-L1 to help the tumor evade the immune system. Inflammatory cytokines from the tumor microenvironment reciprocally enhance EGFR pathway activity. This further strengthens therapeutic resistance.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, under TKI-induced stress, tumor cells may activate protective autophagy (a cellular self-digestion process) as an adaptive survival mechanism. This reveals another target for therapeutic intervention.\u003c\/p\u003e\n\n\u003cp\u003eCollectively, this network of bypass signaling, microenvironmental interplay, and stress adaptation constitutes a multifaceted barrier to durable EGFR inhibition. This provides a compelling biological rationale for pursuing multi-target therapeutic strategies—including natural compounds with multi-target profiles—that can simultaneously suppress EGFR along with these key resistance pathways.\u003c\/p\u003e\n\n\u003ch2 id=\"therapeutic-challenges\"\u003eTherapeutic Challenges and Strategic Opportunities\u003c\/h2\u003e\n\n\u003cp\u003eEGFR-TKIs represent a landmark achievement in precision therapy for EGFR-mutant NSCLC. However, the long-term effectiveness of these drugs is universally compromised by acquired resistance. This resistance is not a single mechanism but a complex network. It includes on-target secondary mutations, activation of bypass pathways, phenotypic transformation, and adaptive remodeling of the tumor microenvironment.\u003c\/p\u003e\n\n\u003cp\u003eBecause resistance is multifaceted, targeting single resistance mechanisms one after another often leads only to the emergence of the next resistance mechanism. Next-generation synthetic TKIs and combination regimens, while advancing the field, frequently encounter inherent limitations. These include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eA narrow spectrum of activity against specific resistance mechanisms\u003c\/li\u003e\n\u003cli\u003eThe potential to inadvertently select for new resistant cancer cell clones\u003c\/li\u003e\n\u003cli\u003eCompounded systemic toxicities (side effects throughout the body) associated with targeted drug combinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere exists, therefore, a clear and pressing therapeutic gap. There is a need for agents capable of simultaneously modulating multiple nodes within the cancer signaling network. These agents must be able to preempt or overcome polyclonal resistance (resistance involving many different cancer cell populations) while maintaining a manageable safety profile.\u003c\/p\u003e\n\n\u003cp\u003eThis gap presents a strategic opportunity for natural compounds. These plant-derived molecules are inherently equipped with multi-target profiles. They can simultaneously influence multiple pathways—such as the core EGFR axis, its key downstream effectors, and critical bypass signals. Combined with their historically favorable toxicity profiles, natural compounds offer a compelling rationale as backbone agents or sensitizers in next-generation combination strategies.\u003c\/p\u003e\n\n\u003cp\u003eThe following sections are organized to critically evaluate each major class of natural compounds—alkaloids, terpenoids, flavonoids, and polyphenols—through a resistance-focused lens. The authors focus on two key abilities:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eThe ability to co-target core EGFR signaling and key resistance-associated bypass pathways\u003c\/li\u003e\n\u003cli\u003eThe ability to synergize with existing TKIs to restore therapeutic sensitivity\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"natural-compounds\"\u003eNatural Compounds Targeting the EGFR Pathway in NSCLC Therapy\u003c\/h2\u003e\n\n\u003cp\u003eThe inherent multi-target nature of natural compounds offers a unique strategic advantage against the complex network of EGFR TKI resistance. Unlike single-target synthetic drugs, these molecules can simultaneously modulate the core EGFR pathway and its key bypass tracks. This positions them as ideal candidates for rational combination therapies.\u003c\/p\u003e\n\n\u003cp\u003eThis section provides a critical synthesis of the major classes of natural compounds. These classes are alkaloids, terpenoids, flavonoids, and polyphenols. The section evaluates their mechanisms and preclinical evidence. The section also evaluates the challenges that must be addressed to realize their clinical potential in NSCLC.\u003c\/p\u003e\n\n\u003ch2 id=\"alkaloids\"\u003eAlkaloids\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eBerberine (BBR)\u003c\/strong\u003e has demonstrated the ability to inhibit the EGFR pathway and synergize with EGFR-TKIs in preclinical studies. Preclinical means the research was done in laboratory cells or animals, not in patients. Berberine works by inhibiting proliferation, migration, and invasion of cancer cells. It also induces autophagy or apoptosis (programmed cell death). Berberine can reverse resistance caused by MET amplification.\u003c\/p\u003e\n\n\u003cp\u003eHowever, these promising results are largely derived from laboratory and animal studies. A significant challenge for berberine is its poor oral bioavailability (the proportion of the drug that enters the bloodstream when taken by mouth) and rapid systemic elimination. This may limit its effective concentration at the tumor site. Some studies report low toxicity in certain normal cells. However, a systematic and comprehensive safety profile has not been fully established in the context of NSCLC treatment. This safety profile includes potential liver toxicity or gastrointestinal effects at therapeutic doses. Its potential interactions with other drugs via cytochrome P450 enzymes also warrant investigation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePiperlongumine (PL)\u003c\/strong\u003e has emerged as a candidate with a dual mechanism against EGFR TKI resistance. It functions as a direct inhibitor of both wild-type and mutant EGFR. At the same time, it promotes the degradation of the anti-apoptotic protein Mcl-1 via the Akt\/GSK3β axis to induce mitochondrial apoptosis. Preclinical studies indicate that piperlongumine synergizes with gefitinib or erlotinib. It also demonstrates antitumor activity in osimertinib-resistant xenograft models (animal models where human tumor tissue is implanted). However, its efficacy in animal models does not guarantee success in humans.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMatrine\u003c\/strong\u003e works by downregulating IL-6, JAK1, and STAT3. It induces apoptosis and shows synergistic sensitization with TKIs in both laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOxymatrine\u003c\/strong\u003e downregulates p-EGFR, p-Akt, and p-ERK. It induces cell cycle arrest and shows synergistic sensitization in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSanguinarine\u003c\/strong\u003e upregulates NOX3 and downregulates MsrA. It promotes oxidation and degradation of EGFR. It overcomes TKI resistance, notably by reversing the T790M-mediated resistance mechanism.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGriffithazanone A\u003c\/strong\u003e downregulates PIM1, induces apoptosis, and shows synergistic sensitization. It can reverse osimertinib resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003ch2 id=\"terpenoids\"\u003eTerpenoids\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCelastrol\u003c\/strong\u003e downregulates EGFR, PI3K\/Akt, and RAS\/MAPK pathways. It induces EGFR degradation, inhibits proliferation, and induces apoptosis. It shows synergistic sensitization and can overcome TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGinsenoside Rg3\u003c\/strong\u003e downregulates PD-L1 glycosylation and HIF-1α\/VEGF\/EGFR. It induces autophagy and inhibits proliferation. It has been studied in laboratory, animal, and clinical settings. It shows synergistic sensitization and can overcome osimertinib resistance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eβ-elemene\u003c\/strong\u003e upregulates AMPK\/MAPK and downregulates EZH2, lncRNA H19, and TFEB. It inhibits proliferation, induces apoptosis, and triggers ferroptosis (a type of iron-dependent cell death) and autophagy. It shows synergistic sensitization and can reverse TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eUrsolic acid\u003c\/strong\u003e downregulates β-catenin\/TCF4\/CT45A2, EGFR, and JAK2\/STAT3. It induces apoptosis and inhibits proliferation, migration, and invasion. It has been studied in laboratory, animal, and clinical settings. It shows synergistic sensitization and can overcome TKI resistance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBetulinic acid\u003c\/strong\u003e downregulates EGFR and PI3K\/Akt\/mTOR. It inhibits proliferation, induces autophagy and apoptosis, and causes cell cycle arrest. It shows synergistic sensitization and can overcome primary TKI resistance in laboratory studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOleanolic acid\u003c\/strong\u003e downregulates PI3K\/Akt\/mTOR and induces apoptosis in laboratory studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOridonin\u003c\/strong\u003e downregulates EGFR\/ERK\/MMP-12 and CIP2A\/PP2A\/Akt. It inhibits proliferation and can overcome gefitinib resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCucurbitacin B\u003c\/strong\u003e downregulates p-EGFR, PI3K\/mTOR, and STAT3. It inhibits proliferation and induces apoptosis in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDihydroartemisinin\u003c\/strong\u003e upregulates ROS degradation and induces ferroptosis. It can overcome EGFR TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCostunolide\u003c\/strong\u003e downregulates MEK1 and AKT1\/2. It can overcome osimertinib resistance in laboratory studies.\u003c\/p\u003e\n\n\u003ch2 id=\"flavonoids\"\u003eFlavonoids\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuercetin\u003c\/strong\u003e downregulates EGFR, ERK\/MEK, Akt\/S6K, NF-κB, and multiple receptor tyrosine kinases (c-Met, Her-2, AXL, IGF1R). It inhibits proliferation and induces apoptosis and autophagy. It shows synergistic sensitization and can reverse TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHyperoside\u003c\/strong\u003e upregulates FoxO1 and downregulates lncRNA CCAT1. It inhibits proliferation and induces apoptosis in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLuteolin\u003c\/strong\u003e downregulates EGFR, ERK, Akt\/mTOR, and NF-κB. It induces apoptosis and autophagy. It shows synergistic sensitization and can overcome TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eApigenin\u003c\/strong\u003e downregulates p-EGFR, EGFR, HIF-1α, c-Myc, PI3K\/Akt, and RAS\/RAF\/MEK\/ERK. It inhibits proliferation, migration, and invasion, and induces apoptosis. It shows synergistic sensitization and can overcome resistance caused by L858R\/T790M mutations in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDihydromyricetin\u003c\/strong\u003e upregulates EGFR, Akt, and survivin. It induces apoptosis and can overcome TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHydroxygenkwanin\u003c\/strong\u003e upregulates EGFR ubiquitination and degradation, and downregulates STAT3, Akt, and ERK. It induces apoptosis and can overcome TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003ch2 id=\"polyphenols\"\u003ePolyphenols\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCurcumin\u003c\/strong\u003e downregulates EGFR, ERK\/MEK, Akt\/S6K, and multiple receptor tyrosine kinases (c-Met, Her-2, AXL, IGF1R). It inhibits proliferation and induces apoptosis and autophagy. It shows synergistic sensitization and can reverse TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eResveratrol\u003c\/strong\u003e upregulates AMPK and downregulates p-EGFR, EGFR, ERK\/MEK, PI3K\/Akt, and Akt\/mTOR. It inhibits proliferation and induces apoptosis, autophagy, and senescence (cellular aging). It shows synergistic sensitization and can reverse TKI resistance in laboratory studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEGCG\u003c\/strong\u003e (epigallocatechin gallate, a compound found in green tea) upregulates EGFR degradation and downregulates MAPK, PI3K\/Akt, and STAT3. It inhibits proliferation and migration, and induces cell cycle arrest and apoptosis. It shows synergistic sensitization and can reverse TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGallic acid\u003c\/strong\u003e upregulates EGFR degradation and downregulates p-EGFR, PI3K\/Akt, and RAS\/ERK. It inhibits proliferation and induces apoptosis. It can overcome TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEllagic acid\u003c\/strong\u003e downregulates EGFR. It inhibits proliferation and induces apoptosis. It shows synergistic sensitization and can reverse TKI resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003ch2 id=\"other-compounds\"\u003eOther Natural Compounds\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eShikonin\u003c\/strong\u003e upregulates ROS and EGFR degradation, and downregulates PI3K\/Akt and MEK\/ERK. It induces apoptosis and shows synergistic sensitization in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSilibinin\u003c\/strong\u003e downregulates EGFR, EMT, PI3K\/Akt, and JAK\/STAT. It inhibits proliferation, migration, and invasion. It shows synergistic sensitization and can overcome acquired resistance in laboratory and animal studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePsorachromene\u003c\/strong\u003e downregulates EGFR and inhibits proliferation in laboratory studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eXanthohumol\u003c\/strong\u003e upregulates Ets-1 ubiquitination and downregulates c-Met. It inhibits proliferation in laboratory and animal studies.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review highlights several important implications for patients with EGFR-mutant NSCLC:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eNatural compounds are not yet ready for routine clinical use.\u003c\/strong\u003e Most of the evidence comes from laboratory and animal studies. Clinical trials in patients are still needed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCombination approaches are key.\u003c\/strong\u003e Natural compounds appear most promising when used alongside existing TKIs, not as replacements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMulti-target effects matter.\u003c\/strong\u003e Because resistance to TKIs involves many pathways, compounds that affect multiple targets simultaneously may be more effective than single-target drugs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDelivery challenges must be solved.\u003c\/strong\u003e Many natural compounds have poor bioavailability and are rapidly eliminated from the body. New delivery systems, such as nano-delivery, may help overcome these limitations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSafety profiles need further study.\u003c\/strong\u003e While natural compounds are generally considered safe, comprehensive toxicity data at therapeutic doses are still lacking for many of these compounds in the context of NSCLC treatment.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Current Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe authors acknowledge several important limitations:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMost studies are preclinical (laboratory or animal studies), not clinical trials in patients\u003c\/li\u003e\n\u003cli\u003eResults in animal models do not always translate to humans\u003c\/li\u003e\n\u003cli\u003ePharmacokinetic limitations (poor absorption, rapid elimination) affect many natural compounds\u003c\/li\u003e\n\u003cli\u003eComprehensive safety data at therapeutic doses are lacking for many compounds\u003c\/li\u003e\n\u003cli\u003ePotential drug interactions with co-administered medications need investigation\u003c\/li\u003e\n\u003cli\u003eThe heterogeneity (variety) of resistance mechanisms makes it difficult to target all pathways with a single compound\u003c\/li\u003e\n\u003cli\u003eStandardized formulations and dosing protocols have not been established\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Future Directions\u003c\/h2\u003e\n\n\u003cp\u003eBased on this comprehensive review, the authors recommend the following directions for future research and clinical development:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eConduct well-designed clinical trials\u003c\/strong\u003e to evaluate the safety and effectiveness of natural compounds in combination with EGFR-TKIs in patients with NSCLC.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelop improved delivery systems\u003c\/strong\u003e, such as nano-delivery platforms, to overcome the pharmacokinetic limitations of natural compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEstablish comprehensive safety profiles\u003c\/strong\u003e for natural compounds at therapeutic doses, including potential liver toxicity and gastrointestinal effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestigate drug interactions\u003c\/strong\u003e between natural compounds and standard NSCLC treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentify biomarkers\u003c\/strong\u003e that can predict which patients are most likely to benefit from specific natural compound combinations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStandardize formulations and dosing\u003c\/strong\u003e to ensure consistent and reproducible results across studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStudy combination strategies\u003c\/strong\u003e that address multiple resistance mechanisms simultaneously.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors conclude that natural compounds should be viewed not merely as standalone agents, but as essential components of rational combination therapies. This approach offers a fresh roadmap for translating these promising agents into clinical practice for precision oncology in NSCLC.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eAre natural compounds ready to be used for EGFR-mutant NSCLC?\u003c\/h3\u003e\n\u003cp\u003eNo. Most evidence for these compounds comes from laboratory and animal studies, not from clinical trials in patients. The authors state that natural compounds are not yet ready for routine clinical use, and that well-designed clinical trials are still needed to evaluate their safety and effectiveness in people with EGFR-mutant NSCLC.\u003c\/p\u003e\n\u003ch3\u003eWould natural compounds replace my EGFR-TKI?\u003c\/h3\u003e\n\u003cp\u003eNo. The authors conclude that natural compounds should be viewed not as replacements for existing TKIs, but as partners in combination therapy strategies. They appear most promising when used alongside drugs such as gefitinib, erlotinib, or osimertinib, with the aim of restoring sensitivity in resistant tumors rather than substituting for standard treatment.\u003c\/p\u003e\n\u003ch3\u003eWhy might compounds that affect several targets help with TKI resistance?\u003c\/h3\u003e\n\u003cp\u003eResistance to EGFR-TKIs is not one mechanism but a network, including secondary EGFR mutations such as T790M and C797S, bypass pathways such as MET and AXL, and phenotypic changes such as epithelial-mesenchymal transition. Because resistance involves many pathways, compounds that affect multiple targets at once may be more effective than single-target drugs.\u003c\/p\u003e\n\u003ch3\u003eWhat limits the clinical use of many natural compounds?\u003c\/h3\u003e\n\u003cp\u003eMany natural compounds have poor bioavailability, meaning only a small proportion enters the bloodstream when taken by mouth, and they are rapidly eliminated from the body. This may limit the concentration reaching the tumor. New delivery systems, such as nano-delivery platforms, are being examined as a way to overcome these pharmacokinetic limitations.\u003c\/p\u003e\n\u003ch3\u003eAre natural compounds safe to take at therapeutic doses?\u003c\/h3\u003e\n\u003cp\u003eWhile natural compounds are generally considered safe, comprehensive toxicity data at therapeutic doses are still lacking for many of them in the context of NSCLC treatment. Potential liver toxicity, gastrointestinal effects, and interactions with other drugs through cytochrome P450 enzymes need investigation. Safety profiles must be established before routine use.\u003c\/p\u003e\n\u003ch3\u003eWhat is the T790M mutation and why does it matter?\u003c\/h3\u003e\n\u003cp\u003eT790M is a secondary mutation in the EGFR gene that restores the receptor's ability to bind ATP, the cell's energy molecule, and is a classic mechanism of resistance to first- and second-generation TKIs. It was later targeted by third-generation TKIs such as osimertinib. Some natural compounds, including sanguinarine, have reversed T790M-mediated resistance in laboratory and animal studies.\u003c\/p\u003e\n\u003ch3\u003eWhat research is still needed before these compounds can be used in patients?\u003c\/h3\u003e\n\u003cp\u003eThe authors recommend well-designed clinical trials of natural compounds combined with EGFR-TKIs, improved delivery systems such as nano-delivery, comprehensive safety profiles at therapeutic doses, investigation of drug interactions, biomarkers to predict who may benefit, and standardized formulations and dosing to ensure consistent results across studies.\u003c\/p\u003e\n\u003ch3\u003eI have EGFR-mutant NSCLC and my TKI is no longer working — when should I seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eResistance to EGFR tyrosine kinase inhibitors is expected and can arise through several mechanisms at once, including new EGFR mutations such as T790M and C797S, bypass pathways such as MET and AXL, and changes in cancer cell character. Because resistance is complex, a second opinion can help clarify which mechanism applies and whether a clinical trial or a combination strategy is appropriate. Most evidence for natural compounds combined with TKIs comes from laboratory and animal studies, not patients, so these agents are not ready for routine use. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Ye B, Xiao Q.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e The Sixth People's Hospital of Huizhou, Huizhou, Guangdong, China; Hunan University of Chinese Medicine, Changsha, Hunan, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Pharmacology, Volume 17, Article 1758414\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e 27 March 2026\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fphar.2026.1758414\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Review\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. The original article is an open-access publication distributed under the terms of the Creative Commons Attribution License (CC BY). The review examined evidence for over 33 representative natural compounds spanning alkaloids, terpenoids, flavonoids, and polyphenols.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47797544485020,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-natural-compounds-for-non-small-cell-lung-cancer-targeting-the-egfr-signaling-pathway-hero.png?v=1791868932","url":"https:\/\/diagnosticdetectives.kr\/products\/natural-compounds-for-non-small-cell-lung-cancer-targeting-the-egfr-signaling-pathway","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}